Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

May 6, 2025

NASDAQ US Health Care Biotechnology earnings 89 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Hello, everyone, and thank you for being with us this afternoon. We'll kick things off with Robert Blum, our President and Chief Executive Officer, who will walk through the quarter's highlights and what's happened recently. Then Andrew Callos, our EVP and Chief Commercial Officer, will discuss preparations on the commercial side for aficamten. Fady Malik, EVP of R&D, will share news about where the aficamten clinical development program stands. Stuart Kupfer, SVP and Chief Medical Officer, will give updates regarding clinical development for both omecamtiv mecarbil and CK-586. Isaac Ciechanover, EVP, Corporate Development and Chief Business Officer, will talk about business development as it fits within our corporate development efforts. Sung Lee, EVP and Chief Financial Officer, will take us through a financial review of the quarter just ended. And last, Robert will go over the key milestones we expect for the rest of 2025. One thing to keep in mind: parts of what we discuss below, including answers we give to your questions, involve statements about future events and performance instead of historical facts, which makes them forward-looking statements. What actually happens could differ materially from what those forward-looking statements project. You can find more details about the factors that might cause actual results to differ materially from what's in these forward-looking statements in our SEC filings, including the current report on our first quarter 2025 financial results furnished today to the SEC on Form 8-K. We have no obligation to update any forward-looking statements after this call ends. Now I'll hand things over to Robert.

Robert Blum

executive
#2

Thanks, Diane. I also want to thank everyone for being on today's call. We got off to a strong start in the first quarter, which gives us a solid base for the growing momentum we're building as we get closer to what could be a pivotal move toward possible commercialization. Naturally, our main priority right now is the new drug application we've filed for aficamten. As we made public last week, the FDA has pushed back the PDUFA date for the aficamten NDA, which covers treating patients who have oHCM, to December 26, 2025, so there's more time to carry out a complete review of the REMS we proposed. Let me be clear: before we submitted the NDA for aficamten, we held a series of three meetings with the FDA, and in those meetings we talked about a variety of subjects tied to what our submission contained, such as safety monitoring and risk mitigation strategies. Those meetings were a top-line meeting where we went over the SEQUOIA-HCM results, a pre-NDA meeting covering particular subjects related to our submission, and a Type B meeting where we talked about strategies for safety monitoring and risk mitigation to support our NDA submission. People from the Division of Cardiology and Nephrology attended all three of those meetings, along with people from the Division of Risk Management within the FDA's Office of Surveillance and Epidemiology. As we've said before, those interactions gave us the chance to talk through, in detail, the data supporting the safety and intrinsic pharmaceutic properties of aficamten and how that data might shape ways to manage risk, and also to learn how the FDA sees this issue. With those interactions in mind, we felt it was reasonable to put forward a separate risk mitigation approach tailored to aficamten and built on labeling and other tools, including voluntary education materials. Still, we gathered from the FDA that whether REMS might be needed would be something the agency would focus on during its review. We decided to go that route because, given the situation, we believed it made sense considering aficamten's profile. Even so, we prepared our separate REMS proposal as a backup, and we were fully ready to submit it should that become necessary. While the NDA was under review, because of how aficamten works, the FDA asked us to submit REMS specific to its intrinsic properties, and we got that to them right away. As we said last week, we recently found out from the FDA that our later submission of the revs counts as a major amendment to the NDA and will therefore mean a standard three-month extension to the original PDUFA action date. As a reminder, we discovered and developed aficamten with the goal of moving it forward as a possible next-in-class cardiac myosin inhibitor. Given its inherent characteristics, we studied it in preclinical and clinical studies to figure out how its half-life, its rapid onset, its reversibility, and an optimized relationship between PK and PD might allow for a unique, convenient dosing regimen. We looked at its DDI profile in depth, in much the same way, to make sure it would allow for a differentiated clinical profile that could back potential differentiation. Our clinical study results, among them SEQUOIA-HCM and FOREST-HCM, in our view support a possible label and risk mitigation profile that, should the FDA grant approval, would set aficamten apart. On that point, nothing has shifted. To state it once more for clarity, the FDA asked for no further clinical data or studies. In an 8-K filing in March, we told you that we finished a mid-cycle review with the FDA during the first quarter. At that meeting, the FDA verified that it has no plans to hold an advisory committee meeting — consistent with what the agency had told us before — and that our late-cycle meeting should take place in June. The PDUFA extension does push back the possible approval of aficamten, yet it leaves untouched our confidence in its distinct benefit-risk and pharmacokinetic profile, and it likewise leaves untouched our expectation for a potentially differentiated label and risk mitigation profile if approval comes. Because the FDA review of the NDA remains underway, we don't plan to offer more color or detailed updates about our communications with the FDA. Turning to other matters, in the first quarter and more recently, we also pushed forward regulatory activities beyond the U.S. In April, the EMA sent us 120-day questions about the MAA for aficamten in Europe, and we are now preparing responses. I'm glad to report that we believe we remain on track for possible EMA approval in the first half of 2026. During the quarter, we also collaborated with Sanofi, our partner in China, to assist the NDA review of aficamten with the NMPA. On the whole, the steady progress of our regulatory interactions around the world encourages us. Shifting to other activities, in the first quarter, we kept ramping up commercial readiness, both in the U.S. and in Europe. As Andrew will explain in more detail, we made key advances during the quarter across all commercial planning work streams. True, the PDUFA date extension will move out certain pieces of our commercial readiness, but launch planning continues. In the first quarter, we also hit meaningful milestones in our ongoing clinical trials program for aficamten. We're happy to announce today that we intend to report top-line results from MAPLE-HCM this month. Should those results be positive, we believe the data could represent a potential label expansion opportunity for aficamten after an initial potential FDA approval in oHCM. Beyond oHCM, we're also centered on nHCM, where there is a substantial unmet need for effective treatments; as recognition and diagnosis of the condition rise, the market opportunity keeps expanding; we're happy to announce today that ACACIA-HCM, our pivotal phase III clinical trial of aficamten in nHCM, finished enrollment in the first quarter, months ahead of schedule, which lets us read out the top-line results in the first half of 2026. Fady is going to walk through that milestone, plus a few other changes we introduced into the study based on what regulators around the world told us. With nHCM becoming more common, our confidence stays high about what aficamten could offer these patients, who have far too few options. Aficamten, for oHCM as well as nHCM, is, as you're aware, the first possible new therapy to come out of our specialty cardiology franchise, which additionally covers omecamtiv mecarbil and CK-586, and both of those are moving ahead in later-stage trials of their own, each in a distinct type of heart failure. What we achieved during the first quarter shows careful forethought, tight stewardship of our resources, and an unwavering dedication to high-quality clinical science — all of it pushing us toward the bold Vision 2030 we've set. On that note, I'll hand things over to Andrew.

Andrew Callos

executive
#3

Appreciate that, Robert. During Q1, we kept moving forward with the planning and rollout of our commercial readiness efforts. Because our PDUFA date has been pushed out by three months, a number of work streams are going to be tweaked, yet our urgency and our launch readiness momentum remain fully intact. Our focus this year has been on creating, standing up, and carrying out the go-to-market strategy, and we plan to keep that momentum going as we head toward the revised PDUFA date in December. In Q1, we kicked off recruiting for our salesforce. With the December PDUFA date in mind, we will rework how we onboard that salesforce while keeping the recruiting timeline we have now, which has gotten off to a very strong start. So far, several thousand applications have come in, a lot of them from exceptionally qualified sales professionals, and most of those applicants bring deep cardiology backgrounds along with established relationships, which gives us a robust talent pool for pinpointing the best candidates for these roles. Late in April, we ran a virtual recruiting webinar aimed at sales professional candidates, and attendance climbed to nearly 1,000; these numbers demonstrate just how much interest there is and how strongly positioned we are to draw in top talent and assemble an outstanding sales organization. At the same time, we kept working on sales operational planning, covering analytics, targeting, incentive comp, and putting the finishing touches on the sales training curriculum. We are additionally standing up our tailored patient support program by weaving our strategic partners into one seamless, patient-centered implementation; we also wrapped up choosing our channel distribution partner along with our specialty pharmacy partners. Throughout the quarter, we kept polishing our promotional launch campaign aimed at HCPs and patients, factoring in the latest market dynamics, HCP advisory boards, and primary market research testing. Meanwhile, our unbranded disease awareness campaign, HCM Beyond the Heart, carried on. The campaign targeted at HCPs urges them to weigh the wider HCM burden and deliver whole-person care. In the same way, the campaign for patients assists in teaching those living with HCM about not only the condition itself but also the holistic burden that HCM imposes. We likewise kept up our dialogue with payers and intend to keep educating them about the data from the aficamten clinical development program, along with the clinical and economic burden of HCM; beyond the disease burden, we anticipate several HEOR presentations at upcoming meetings that will further characterize both oHCM and nHCM and sharpen understanding of this disease. On that note, one thrilling milestone in Q1 was the debut of EARTH-HCM, an interactive, open-access, online public health education tool that we created alongside leading academic institutions. Beyond our U.S. commercial planning, we moved European commercial readiness work forward in a gated fashion, which included bringing on key leadership for marketing, finance, legal, compliance, and human resources. We established new regional entities in France and the U.K., each with in-country leaders. During the quarter, we also confirmed our reimbursement strategy and the sequence for country launches, which, as we have said before, kicks off with Germany in 2026, subject to EMA approval. Last, we started preparing dossiers for HTA submission across several geographies. In closing, our commercial readiness work advanced during the last quarter, and we will keep working to complete a strong commercial framework that can back the possible launches of aficamten in the U.S; and Europe. Having said that, I'll hand things over to Fady, who will discuss news about the clinical trial program we have underway for aficamten.

Fady Malik

executive
#4

Appreciate that, Andrew. Like Robert said, our plan is to share topline data from MAPLE-HCM during this month, and then present the primary findings at a medical conference toward the end of this year. We'd like to frame expectations right now that the topline disclosure will be qualitative in nature, since we don't want to put that major medical meeting presentation at risk by putting out specifics of what we found. As a refresher, MAPLE-HCM was built as a stringent trial that randomizes individuals to get either aficamten or metoprolol, both given as monotherapy. Beta blockers do represent the standard of care in HCM, yet how they affect exercise performance, symptoms, and LVOT gradients in structural HCM hasn't been well defined. Meanwhile, understanding how aficamten works as monotherapy across those same measures matters, because that knowledge will guide how cardiac myosin inhibitors get folded into standard practice. We're eager to see what the head-to-head data from MAPLE-HCM show, since it could help set apart what aficamten does for exercise capacity, symptoms, and cardiac structure and function, plus its safety and tolerability profile, versus the long-standing standard of care, metoprolol. There are also several key updates on ACACIA-HCM we want to share. To start, we're happy to say that during Q1 of 2025, roughly half a year earlier than planned, we finished enrolling patients for the trial's primary cohort, which covers every site across North and South America, Australia, Europe, China, and Israel. A total of 516 patients got randomized in just 18 months, and that speed came from strong interest in taking part, which sped up screening and enrollment through the close of 2024 and into the start of 2025. The primary cohort of ACACIA-HCM covers the geographies we originally set for enrollment back when the trial began in 2023. That said, in connection with the collaboration and licensing deal we signed with Bayer for aficamten in Japan late last year, we also decided to extend ACACIA-HCM into Japan, aiming for a DART in Q2 2025 to back its possible marketing authorization for nHCM. Because the primary cohort finished enrollment months sooner than expected, we split ACACIA-HCM into two parts: the primary cohort and the Japan cohort — a strategy that regulators in Japan endorsed. With enrollment in the primary cohort now done, we anticipate sharing topline results from it during the first half of 2026. Also, early in Q1, we began the process of revising ACACIA-HCM's primary endpoint, moving from a single primary endpoint of KCCQ clinical summary score with a first secondary endpoint of exercise capacity to a dual primary endpoint consisting of change in KCCQ clinical summary score and a measure of exercise capacity, pVO2, with each assessed as a change from baseline at week 36. We made this adjustment so the trial's endpoints would line up with feedback from regulators outside the U.S. and so its interpretation would be consistent worldwide. Before this revision, CPET measurements were already being gathered for every patient, so the change leaves how the clinical trial is run unaffected. What this does is simply move one measurement of exercise performance up from being the first secondary endpoint to becoming another primary endpoint. Because ACACIA-HCM enrolled so quickly, we made this adjustment knowing we could still adequately power the study by raising the sample size from 420 to at least 500 patients, which ensures 90% power at an alpha of 0.025 for each primary endpoint, enough to detect a conservative clinically meaningful change. For KCCQ versus placebo, that difference is 5 points. For pVO2, it comes to 1.0 milliliter per kilogram per minute. Make no mistake, though: if either clinical endpoint making up the dual primary endpoint reaches statistical significance, ACACIA-HCM will be deemed positive. All in all, we think these modifications maximize the likelihood that this trial succeeds and will likewise meet regulatory requirements around the world. As a reminder, cohort four of the phase II trial, REDWOOD-HCM, looked at aficamten treatment in nNHCM in an open-label manner, showing improvements in KCCQ and NYHA functional class along with an average NT-proBNP reduction of 66%. Most patients reached the highest dose available, 50 mg, and no one discontinued the drug because of low ejection fraction, with only a few cases of LVEF below 50%. Those same findings appeared once patients moved into the open-label extension trial, FOREST-HCM. Importantly, ACACIA-HCM takes the phase II experience further by adopting the identical dosing strategy, reaching target dose rapidly within 8 weeks, refining entry criteria, and selecting patients carefully through echocardiographic review conducted by HCM specialists. Even though nHCM makes up roughly one-third of the HCM population right now, it is being diagnosed far more quickly than oHCM. Consequently, we expect nHCM will eventually account for close to half of all HCM diagnoses. Should ACACIA-HCM produce positive results, that would mean a major opportunity to assist this underserved patient population, whose treatment options are currently limited. To wrap up the updates on our clinical trials program that is ongoing, CEDAR-HCM enrollment keeps moving forward, and we stay on schedule to finish enrolling the Adolescent cohort during the second half of this year. As you have heard, the first quarter brought strong progress in pushing ahead the ongoing aficamten clinical trials program, which we believe will open the door to multiple opportunities for reaching more patients living with HCM across the globe. Now, I will hand things over to Stuart.

Stuart Kupfer

executive
#5

Thank you, Fady. It's a pleasure to share where things stand with the programs in our later-stage development pipeline. Over the quarter, we kept Amber-HFpEF up and running — that's the phase II study of CK-586 in individuals who have symptomatic heart failure with preserved ejection fraction of at least 60%. Our objective of finishing enrollment for the initial two cohorts during the back half of this year remains something we keep moving toward. Roughly 2 million Americans living with heart failure have an ejection fraction at or above 60%. Even with therapeutic progress and widespread adoption of standard of care regimens, outcomes for these individuals are frequently poor after being hospitalized for heart failure, and their rate of returning to the hospital is high, which in turn pushes healthcare costs upward. The need for improved treatment choices for these patients is unmistakable, and our view is that Amber-HFpEF will assist in clarifying whether a cardiac myosin inhibitor could provide benefit to this subset of heart failure patients, while extending what we've learned in non-obstructive HCM. Enrollment also continues in COMET-HF, our confirmatory phase III study of omecamtiv mecarbil among patients with symptomatic heart failure whose ejection fraction is severely reduced, below 30%. We keep making headway bringing sites in the U.S. online, and at the close of April we held a U.S. investigator meeting that drew strong attendance. At that gathering, we were delighted by how engaged the investigators were, which mirrors their understanding of how urgent it is to develop safe and effective therapies for this high-risk group, along with their eagerness to get patients enrolled. A number of these investigators took part in GALACTIC-HF, the initial phase III study of omecamtiv mecarbil. Enrollment in COMET-HF should carry on through this year, with completion anticipated in 2026. Following aficamten, our later-stage pipeline stands as our next biggest opportunity, offering numerous chances to make a positive difference for patients facing adjacent cardiovascular conditions with substantial unmet need. With that, I'll hand things over to Isaac.

Isaac Ciechanover

executive
#6

Appreciate that, Stuart. During Q1, we took part in a Series B round for Embryo Pharmaceuticals, aimed at helping push forward Ninoraf Foxstat as a treatment for nHCM. This marks our inaugural equity investment where we're able to both take part in and offer guidance on developing a novel therapy within the cardiometabolic area — something that could matter to us down the road, all without dedicating major financial or operational resources. As laid out in our Vision 2030, innovation from outside and business development stand as a core pillar of how we intend to grow. Everything in our present R&D pipeline came about through internal discovery, and we believe there's a substantial chance to build on and strengthen that base via investments, partnerships, and licensing deals. When we engage in a selective, prudent way with chances to externalize innovation as a counterbalance to our own R&D work, our goal is to reach more novel science, move into neighboring therapeutic fields, and in the end speed up development of new therapies for patients. Crucially, we stay open to every strategic lever so we remain the partner of choice and keep our standing as both pioneer and leader in muscle biology. With that, I'll pass things to Sung.

Sung Lee

executive
#7

Appreciate that, Isaac. We're glad to share the results for our first quarter of 2025. Beginning on the balance sheet side, we closed out the first quarter with roughly $1.1 billion in cash, cash equivalents, and investments, versus $1.2 billion when the fourth quarter of 2024 came to an end. During the first quarter of 2025, cash, cash equivalents, and investments fell by about $132.2 million. R&D expenses came in at $99.8 million for the first quarter, compared with $81.6 million during the same period in 2024. That rise was driven mainly by moving our clinical trials forward along with greater personnel-related costs. G&A expenses for the first quarter of 2025 totaled $57.4 million, versus $45.5 million during the same period in 2024. This increase largely reflected investments in commercial readiness activities as well as greater personnel-related costs. Net loss for the first quarter of 2025 reached $161.4 million, or $1.36 per share, versus a net loss of $135.6 million, or $1.33 per share, during the same period in 2024. Now to our financial guidance: we are keeping our full-year 2025 financial guidance in place, with GAAP operating expense projected to land between $670 million and $710 million. Stock-based compensation included within GAAP operating expense should come in between $110 million and $120 million. Taking stock-based compensation out of GAAP operating expense gives a range of $550 million-$600 million. Although the guidance range has not changed, two dynamics shift expenses within that range in a meaningful way. First, the range incorporates the U.S. PDUFA date extension for aficamten, which we expect will push G&A expense lower, largely because of the adjusted timing of launch expenses. Second, the range accounts for the acceleration and increased enrollment of ACACIA, our phase III trials of aficamten in nHCM, which will push R&D expense higher. In light of the U.S. PDUFA date extension, we will keep watching the pace of pre-launch investments and update you as appropriate. Our balance sheet remains a source of strength, and we are well-positioned to fund the potential launch of aficamten in the U.S. later this year and advance our pipeline; with that, I'll hand it back to Robert.

Robert Blum

executive
#8

Thanks, Sung. We saw substantial advancement throughout our business during Q1. Because of the unpredictable conditions in the broader market where we compete, it's good to be in a favorable spot—our robust balance sheet and cash reserves are the product of deliberate strategizing and readiness during 2024, which positions us to carry out every one of our critical objectives in 2025. As we look toward the coming months, plenty lies ahead for us as an organization—above all, the possible FDA green light for aficamten near the close of this year, followed by our complete shift into an integrated commercial biopharmaceutical company, plus the short-term top-line data from MABLE-HCM. With all these things progressing while we keep running several other later-stage clinical studies and maintain our research efforts, our outlook stays promising as we push forward with Vision 2030, built upon our trailblazing roots in muscle biology; we've never been nearer to bringing the advantages of our science to bear in ways that could potentially change the lives of patients suffering from muscle dysfunction diseases. Now let me go over the milestones that lie ahead. Regarding aficamten, we anticipate pushing forward with NDA review work alongside the FDA to back the possible U.S. clearance of aficamten during the latter half of this year. We anticipate moving ahead with go-to-market approaches and getting ready to launch Aficamten commercially across the United States during the latter half of this year, assuming the FDA grants approval. We anticipate carrying on go-to-market initiatives in Germany and broadening commercial readiness efforts throughout Europe in 2025, getting ready for possible EMA approval during the first half of 2026; we anticipate working alongside Sanofi to back the possible clearance of aficamten in China, contingent on NMPA approval, and we anticipate top-line findings from MAPLE-HCM within this month. We likewise anticipate sharing top-line findings from the primary cohort of ACACIA-HCM during the first half of 2026 and kicking off patient enrollment for the Japan cohort of ACACIA-HCM during this quarter. We anticipate finishing enrollment for the adolescent cohort in CEDAR-HCM during the latter half of this year. Regarding omecamtiv mecarbil, we anticipate carrying on patient enrollment in COMET-HF throughout 2025 so that enrollment can be finished in 2026. Regarding CK-586, we anticipate finishing enrollment for the initial two patient cohorts in Amber-HFpEF during the latter half of this year. Lastly, concerning preclinical development and continuing research, we anticipate carrying on ongoing preclinical development along with research work aimed at further programs centered on muscle biology. Operator, having said that, let's now open the call for questions, please.

Sean McCutcheon

executive
#9

Good afternoon. Hey, everyone. Appreciate the — Hi, Robert. Appreciate the question. So, given what happened with Odyssey and the way BMS describes obstructive HCM as distinct from non-obstructive, there are a lot of questions coming in about what that means for ACACIA. Could you talk about how ACACIA was designed around aficamten's properties to increase the probability of success, and how do you think about the importance of pushing the CMI dose higher in non-obstructive disease, since you managed to get the majority of patients onto that 20 mg dose in the first non-obstructive cohort? Thanks.

Robert Blum

executive
#10

Okay, I'll keep this at a broad level and then have Fady address the particular items you raised. First, regarding ACACIA-HCM, it makes us quite enthusiastic that enrollment was finished in the way it was — sooner than planned, with such keen involvement worldwide. That said, please recognize too that carrying that identical dosing schedule into phase III, and going to sites where aficamten experience is, in our view, already substantial, leaves us hopeful about what the trial may show in the end. You've heard us mention nHCM in connection with REDWOOD cohort four as well, and how we think it points encouragingly toward what testing that same hypothesis in phase III ought to deliver. Our outlook on ACACIA remains highly positive; with that, I'll hand things to Fady so he can take the particular questions.

Fady Malik

executive
#11

Right, I'd say the things Robert brought up are the key ones. With ACACIA's design, we could model it quite closely on our phase II experience — specifically cohort four of REDWOOD-HCM — so the dosing ended up basically identical, though we did add a higher dose in ACACIA. That same dose has been used quite successfully in FOREST-HCM, so the nHCM patients out there can get the 20-milligram dose, and a number of them are on it right now. In REDWOOD, we observed hardly any treatment interruptions and zero discontinuations due to intolerance. Those factors matter a great deal, I believe. How you dose, hitting the correct dose, the dosing schedule — that's frequently among the most decisive elements in whether a phase III trial succeeds. On top of that, I'd say we once again feel confident in the phase II data regarding KCCQ and NYHA class improvement; pVO2 wasn't assessed in phase II, just as we didn't assess it in SEQUOIA for the oHCM patients either. Given symptom and functional class improvement, we again anticipate seeing some pVO2 improvement. Our power is strong enough to detect even a modest pVO2 change. One final thing I'd mention: we stuck with sites where we had substantial experience and that we had screened very rigorously. Essentially, we have a group that examines each patient enrolled in the trial to confirm they not only satisfy the entry criteria but also that their imaging matches what you'd anticipate in nHCM; because of all that, our optimism about ACACIA-HCM's odds of succeeding remains high.

Robert Blum

executive
#12

Thank you.

Sean McCutcheon

executive
#13

Thank you.

Salim Syed

analyst
#14

Hi, Robert. Good afternoon. I appreciate the question and all the information today. I suppose I'll simply pose the evident query regarding aficamten. I just want clarity. At first, did the FDA instruct you not to file the REMS? What took place? Was it an internal matter at the FDA, or was there something within the package that led them to alter their position, so to speak, and request that you in fact file the REMS? If you could give some detail on that. Thank you.

Robert Blum

executive
#15

Certainly. I grasp your desire for additional specifics. I'll tell you whatever I'm able, but kindly realize I might be quite careful with my wording. As you likely understand well, whenever you have these exchanges with FDA prior to an NDA submission, they provide feedback in answer to inquiries. As you've probably gone through the summary basis of approval for mavacamten, and you're aware that FDA advised filing a REMS before that took place; with us, that did not occur. With us, we got no such advice. Actually, we talked about safety, risk mitigation, and from that conversation, we judged it sensible to file the way we did absent a REMS. That wasn't a oversight. We grasped perfectly the feedback we were getting, and we chose to move forward with the submission minus a REMS. FDA accepted it without a REMS. It was while the review was underway that FDA informed us they wanted us to file a REMS. We cannot know everything happening inside FDA that drove their desire for a REMS. As you're aware, much is occurring around and within FDA; we do know we were thoroughly ready for that situation where FDA would later determine during review that a REMS was suitable. They did. It was at that point that we filed the REMS. As is separate, as we think aligns with feedback we got from FDA concerning inherent characteristics or intrinsic properties of aficamten. I believe that will have to be enough for what we can disclose. We don't wish to convey anything that might be considered speculation because, honestly, we don't know everything that led to FDA's request of us. I've told you what we know and the choice we reached given the feedback we had gotten.

Salim Syed

analyst
#16

Okay. Helpful. Thank you very much.

Robert Blum

executive
#17

Thank you.

Gina Wen

analyst
#18

Good afternoon. Gina Wen here, actually — calling in from Barclays. Rob, picking up on what you said, I'm not sure whether you're able to address this, but could you let us know if the REMS program that went to the FDA matched the version shown to investors — that particular protocol — was it the same one you shared when you filed it with the FDA? And separately, in light of this unfortunate event, is there an opportunity to capitalize, since the PDUFA comes with just a single extension and the FDA is not permitted to grant a second one? Could you leverage the MAPLE data, attempt to file that MAPLE data, and seek to have it incorporated into the label for the December 26 approval?

Robert Blum

executive
#19

Let me take your second question first. It is not our intention to file the MAPLE data within this review cycle for AFI Campus in oHCM; doing so would amount to a separate submission that the FDA would likely not welcome, considering how advanced they are in the current review. Our intention, should positive MAPLE results come in later this quarter, is to act quickly to enable a later submission, one that would come after a possible approval of AFI Campus in oHCM. On your first question, I'd appreciate a bit of clarification, please. What you asked is whether the REMS we filed aligns with something we showed investors. We have not.

Gina Wen

analyst
#20

Correct. Or similar to what was communicated earlier — for instance, dosing frequency would be from week 2 through week 8. I'm attempting to extract the concrete details you previously provided to investors. I'm just curious whether you — and also the minimal, meaning the particular monitoring protocol — was that in line with what you put forward as your expectation for how it would stand apart from CAMZYOS's REMS program?

Robert Blum

executive
#21

Yes. Kindly also keep in mind that, to protect our competitive position, we won't disclose detailed specifics about the REMS that we filed. I'll have Fady describe, in broad terms, our approach to safety and risk mitigation.

Fady Malik

executive
#22

Right. Hey Gina. What we turned in, I believe, lines up with everything we've consistently described as aficamten's differentiated characteristics. Just like with FOREST-HCM, we changed the protocol so that monitoring at six-month intervals would allow the dosing window to be broadened from once every two weeks to a range of two to six or eight weeks, letting physicians steer dosing themselves. I'd say we've been transparent, and we shared that data not long ago at American College of Cardiology. There aren't really any drug-drug interactions that matter clinically for us. All of those attributes, you'd expect, were factored into how a REMS program was designed, and we believe it will stand apart and be embraced by the physicians who treat these patients.

Gina Wen

analyst
#23

Thank you.

Robert Blum

executive
#24

Thank you.

Fady Malik

executive
#25

Thank you.

Robert Blum

executive
#26

Hey, Paul.

Paul Choi

analyst
#27

Good afternoon, everybody. Thank you for taking my question. Robert, you mentioned earlier that aficamten is going to be differentiated, but perhaps to build on what Fady was saying, given the recent label updates, which removed certain drug-drug interaction warnings and also the extended monitoring, pushing the monitoring period out to six months — I think many investors are simply asking what remains available for aficamten to stand apart here. If you could perhaps add any further points to help make that clearer, it would be useful. Thanks for taking our question.

Robert Blum

executive
#28

Sure. Once more, speaking broadly, without going into details, if you don't mind, I'll fix one thing you said. Regarding DDIs and regarding echo monitoring, changes were made to the existing CAMZYOS REMS, yet limitations still exist when it comes to DDIs. Limitations also still exist when it comes to echo monitoring, certainly through the up-titration phase, and also through the maintenance phase for specific patients. I'd respond to your question this way. In our view, there is still plenty of room for differentiation grounded in the REMS that we have submitted.

Robert Blum

executive
#29

Hey, Cory.

Cory Kasimov

analyst
#30

Hi, Robert. Hello, everyone. I appreciate you letting me ask. What I want to know is whether a REMS was included when you filed with the EMA. If it wasn't, did that come up among the questions on your day 120 list? Thanks.

Robert Blum

executive
#31

When it comes to an MAA submission with EMA, there isn't a REMS as such, though clearly there are approaches one would want to use to guarantee safe use and reduce risk. Maybe I'll hand things over to Fady so he can say more.

Fady Malik

executive
#32

Right. EMA handles this in another way — there isn't a REMS program as such on their side. What they do require is that you file a risk mitigation program, or RMP, as a routine component of any filing, and that's what we did. Once more, we aren't anticipating any modifications, so to speak, no further filings over in Europe tied to this. It's quite unlike how things are handled in the United States.

Robert Blum

executive
#33

Answering what you asked, as things stand we've gotten the day 120 questions and are moving forward with our replies, and we feel that what we handed in serves us well.

Roanna Ruiz

analyst
#34

Hi, everybody. Good afternoon. I have a question regarding the ACACIA trial. Could you elaborate a little more on the advantages and disadvantages of switching the primary endpoint to a dual primary consisting of peak VO2 and KCCQ? I was also wondering whether you might provide additional specifics about the statistical plan currently in place for ACACIA, if you're in a position to share anything regarding that dual primary endpoint. That would be extremely helpful.

Robert Blum

executive
#35

Yes. Prior to having Fady respond, let me just say that, from my perspective, this provides us with two chances to succeed with ACACIA. Extending what we have observed with aficamten, both in oHCM and in REDWOOD cohort 4, this is encouraging given the way we moved forward with the design and conduct of ACACIA. Perhaps Fady can offer you greater detail.

Fady Malik

executive
#36

Okay, so whenever we put ACACIA together, a key goal for us was ensuring the study ran as efficiently as it could. At that point, we had no idea—and honestly, no one did—what enrollment for an nHCM trial would look like or how fast patients would come in. So the smartest approach is to pick one primary endpoint and put all of the alpha behind it. Then your secondary endpoint becomes whatever matters most after that. Should the first one hit, the entire alpha—that 0.05—carries over to the second endpoint; the FDA gave its backing to that strategy. Naturally, even if the study succeeded on that initial primary endpoint, they still expected to see consistency across several endpoints, exercise performance included. The ACACIA design we initially proposed was genuinely the most efficient way to accomplish that. With those 420 patients, we're well-powered. Regulators elsewhere simply didn't view it the same way the FDA did. Once we received guidance in Europe and in Japan, they pushed far harder for a dual primary endpoint consisting of two components—KCCQ as one, peak VO2 as the other. Instead of letting that become a review problem, we also had a fortunate development: near the end of last year, patient enrollment started picking up substantially, making it quite practical to bring in additional patients and keep regulators worldwide satisfied by adopting a dual primary endpoint with no loss of power; each is powered at 90% and basically lets us evaluate KCCQ and peak VO2 side by side. If both endpoints are met, the following secondary endpoint gets tested at 0.05. If only one of the two succeeds, then the next secondary endpoint—NYHA class—gets tested at 0.025. And again, to be clear, both endpoints plus the secondary endpoints, even at 0.025, carry more than 90% power given the enrollment increase; we believe this places us in the strongest possible spot to truly satisfy regulators globally once everything is finished. In the end, it doesn't alter how the trial is interpreted, which, I believe, regulators require—they require both. My sense is they want to see symptoms and exercise performance both come out consistent. Hopefully, that's.

Roanna Ruiz

analyst
#37

Got it. Yep. Helpful. Thank you.

Robert Blum

executive
#38

Thank you.

Akash Tewari

analyst
#39

Hi there, Akash here. Just a few items. Regarding real-world data, what evidence would need to be presented to the FDA for the possibility of moving to an annual echo requirement as time goes on? Have you already begun that conversation with the agency? And to make sure I understand correctly, does Cytokinetics feel assured that a differentiated REMS for aficamten would be an educational REMS rather than an OTATSU one? Many thanks.

Robert Blum

executive
#40

Okay. Once more, I want you to know that we're not going to respond to every detailed question about what sets things apart inside the REMS itself. When you ask about how often echo monitoring happens, that falls into the same category as how we handle other topics. It's probably better if we don't get into specifics. What I can tell you is that assuming an OTATSU REMS seems reasonable to us. That is the stance we have.

Akash Tewari

analyst
#41

Thanks.

Robert Blum

executive
#42

Hello, Charles.

Charles Duncan

analyst
#43

Good afternoon. Hi, Robert. Good afternoon. I appreciate you taking my question, and congratulations on the progress. I have what I'd describe as a question with several parts, all on one topic. It concerns MAP-HCM. I fully respect the approach taken with the FDA, but are you considering a similar kind of approach when it comes to filing MAPLE afterward with the EMA, and also in China with the NMPA? If that's the case, what's the reason?

Robert Blum

executive
#44

Good question. I'll turn that to Fady, please.

Fady Malik

executive
#45

Right, Charles. I'd say the response doesn't really change from one jurisdiction to another: if we were to add MAPLE-HCM to a filing that's already fairly far along in review, that would create a fair amount of disruption. That isn't something we intend to do. What we intend is to file it after we secure approvals in those jurisdictions.

Charles Duncan

analyst
#46

Okay. Looking forward to that data.

Robert Blum

executive
#47

Thanks, Charles.

Robert Blum

executive
#48

Hi, Tess.

Tessa Romero

analyst
#49

Thanks. Thanks a lot. Good afternoon. At any point across those three meetings you described prior to the filing of your NDA, did the FDA say they felt a REMS wouldn't be needed? Why wasn't it disclosed that no REMS had been submitted at the time the NDA went in? When precisely did the FDA ask for the REMS? Thanks.

Robert Blum

executive
#50

I'll try my best to address those. When it comes to what the FDA conveyed to us, I'd rather not share it, since I believe that communication belongs to the FDA. What I can share is how, drawing on FDA feedback, we reached our determination about the right course. That's what we're sharing today. Should aficamten win approval in the end, my expectation is that a summary basis of approval will set all of this out, so you can understand it then. I hope you appreciate that given that our interactions with the FDA are still ongoing, it wouldn't strike me as sensible for us to have this unfold publicly in any manner that the FDA could in the end find concerning. That's point one. Second, you asked about when this information reached us. It reached us quite promptly, close to when we communicated, as we did, that we'd reached this decision and were receiving FDA feedback on the amendment. The REMS went in not long ago, and not long ago the FDA responded, saying that after reviewing the REMS, they regard this as a major amendment. Have I covered your questions?

Tessa Romero

analyst
#51

You certainly did. What I'm wondering is this: when the NDA went in, why wasn't there any disclosure that no REMS had been filed?

Robert Blum

executive
#52

Well, doing so would have been out of the ordinary, against standard practice, and for sure it might have eaten into the competitive edge we'd have later on. We didn't view that as something we had to disclose; actually, the opposite — since no REMS was submitted, we stayed extremely careful about our language, saying we felt that once approved, aficamten would have a safety and risk mitigation profile that set it apart. You'll see we never stated with REMS, nor did we state without REMS. It was only when we were asked to file a REMS that we did so, and at that point our messaging shifted to say we anticipate that the differentiation would sit within the REMS.

Tessa Romero

analyst
#53

Thank you.

Robert Blum

executive
#54

Thank you.

Maxwell Skor

analyst
#55

Thanks. I appreciate you fielding my question. I'll likely take a somewhat different tack here, or at least attempt to. Since the CAMZYOS REMS got updated not long ago, you filed a 120-day safety update coming out of the FOREST-HCM trial. What I'm curious about is whether the REMS that you recently handed to the FDA might differ from whatever you'd have turned in alongside the initial filing, or from what came up in your pre-NDA discussions. Thanks.

Robert Blum

executive
#56

Yeah; things are moving around a lot here. What we'd perhaps have filed, if a REMS had gone in during 2024, is — looking back — guesswork that I'd rather not get into. All I'll say is that we've kept a very close watch not just on what we discuss with FDA, but likewise on the way FDA went about revising the REMS program for CAMZYOS. Our view is that the REMS we submitted would allow for a differentiated, distinct profile.

Maxwell Skor

analyst
#57

Great. Thank you.

Robert Blum

executive
#58

Thank you.

Leonid Timashev

analyst
#59

Hi there, and thanks for fielding my question. I thought I'd spare you all yet another round of REMS talk. What I'm really wondering about is nHCM. Clearly, since just a single therapy might win approval soon — that being yours, I believe — how do you view the implications for how readily aficamten could be adopted in nHCM should it get the green light? In other words, do you anticipate greater patient warehousing, and as a result a faster launch, or would you rather have had somebody else develop that market first? And regarding the E.U. versus the U.S., you've mentioned that ultimately 50% of patients come from nHCM. Does that pattern apply only in the U.S., or does it hold in both regions? Thanks.

Robert Blum

executive
#60

Those are good questions. Let me hand it over to Andrew Callos to address them, please.

Andrew Callos

executive
#61

Absolutely. Looking at it through the nHCM lens, the rate at which diagnoses are being made has been climbing quite sharply. My view is that when you carry out market development efforts for HCM, those efforts aren't confined to obstructive HCM alone — they truly span the broader disease. As for how nHCM gets adopted, my expectation is that it would happen more quickly than oHCM, given all that market development activity, given how physicians are using CMIs, and given growth past the existing prescriber base. With MAPLE and with what aficamten brings in terms of its properties, we're already contemplating having the capacity to reach beyond the centers of excellence. My sense is that MAPLE would speed that up, and ACACIA would speed it up even more. If both MAPLE and ACACIA read out positively, there would probably be a halo effect, so to speak, when it comes to utilization across obstructive as well as non-obstructive disease.

Robert Blum

executive
#62

Hey, David.

David Lebowitz

analyst
#63

I really appreciate you giving me the chance to ask. Since beta blockers may not be the strongest option — they're low-cost, and a broader range of physicians prescribes them — how would you describe what kind of market opportunity MAPLE actually represents?

Robert Blum

executive
#64

Sure. Our position hasn't changed: should MAPLE turn out positive, and if that eventually gets mirrored in guidelines, we see it adding incrementally rather than transforming what we think the adoption curve for aficamten could ultimately look like, and it might open the door to greater category penetration, particularly among cardiologists who could be quite at ease prescribing beta blockers. You're right on that point. They don't cost much. From the payer perspective, they'd probably want to see the guidelines updated to reflect using a CMI as first-line therapy for patients. Andrew has conducted some market research on this, and he might have more to share.

Andrew Callos

executive
#65

Yes. I’d just add one point, and it’s the same thing Robert mentioned: if you’ve got a second data set — assuming it reads out positively, with MAPLE coming back positive — a second data set that backs up efficacy, backs up safety, and supports the guidelines, that typically drives greater penetration in CMI use. Put plainly, more doctors treating more patients are going to use a CMI than they would if MAPLE weren’t there. There’s also more share potential for aficamten. You really capture all of those benefits together once you bring in a second data set in the same disease area. Based on what our research shows, I do believe it will open the door to wider penetration into community cardiology.

David Lebowitz

analyst
#66

Understood. I appreciate you fielding my question.

Robert Blum

executive
#67

Assuming the data come back favorable — and that's certainly our hope — we'd be able to conduct additional market research focused on that specific profile. That could help shape how we communicate later on. From where we stand right now, that's how we're looking at it.

David Lebowitz

analyst
#68

Thanks.

Mayank Mamtani

analyst
#69

Hello, good afternoon, and thank you for taking our questions. There are essentially two process-related items I'd like to ask about quickly. First, could you share your level of confidence that the REMS filing you just submitted will be cleared without any changes? Second, regarding the upcoming follow-up to the late-cycle meeting in June, what sort of update should we expect to hear from you? Broadly speaking, do you think input from physicians who are independent — for instance, through an advisory committee — might be useful to both the agency and the community at this point, especially given that by that time the MAPLE-HCM data would be available to support a clear AFI differentiation?

Robert Blum

executive
#70

That sounded like three separate questions, so let me see if I can recall the first one. I think you were asking whether I expect the REMS in its submitted form to get cleared without changes. In practice, that almost never happens — there's invariably some dialogue back and forth. That's precisely why, in our view, the FDA designated the filing as a major amendment. With the deadline now pushed out, we're confident there's plenty of runway to work through those items. As for your third question, it had to do with the advisory committee. Since the FDA has indicated an adcom isn't anticipated, we aren't planning for one either. From what we've discussed in this conversation, nothing leads me to see that shifting. If I understood you right, you floated the idea that an adcom might work in our favor. At this stage, I just don't see that as realistic.

Mayank Mamtani

analyst
#71

Right. So, I guess there would be additional data that could be presented in a public setting regarding what this drug looks like, particularly around the initiation of treatment and the echocardiogram monitoring involved. I'm not sure — could the agency gain something from getting that kind of independent input from physicians in a forum of that nature? What are your thoughts on that?

Robert Blum

executive
#72

Like we've said previously, whether an AdCom gets convened or doesn't, in my view, hardly ever hinges on matters that fall under a REMS. The advisors who make up an adcom generally don't bring expertise related to REMS, since risk mitigation at FDA is what they evaluate; having one would be, I think, a pretty unusual sort of adcom. I don't see that as something investors or analysts ought to be concerned with. Your second question, I believe, had to do with — what was it, Andrew? The late-cycle meeting. From what FDA has communicated to us, we anticipate that happening during this second quarter, in June.

Mayank Mamtani

analyst
#73

Thank you, Robert. Very helpful.

Robert Blum

executive
#74

Thank you.

Kripa Devarakonda

analyst
#75

Hey, everyone. I appreciate you answering my question. Robert, I apologize for dwelling on the REMS topic, but I just want to confirm I got it right. You mentioned that FDA gave you no direction to file a REMS, while for mavacamten, guidance was provided to them. You also noted that in those meetings — the 3 you referenced — they respond to questions with feedback. From what you're describing, would it be reasonable to think you inquired with the FDA about whether a REMS should be submitted? And given the feedback, you determined it was appropriate not to file a REMS program.

Robert Blum

executive
#76

I believe that's accurate.

Kripa Devarakonda

analyst
#77

All right, thanks. I'll keep it to a single question.

Robert Blum

executive
#78

Appreciate it.

Jim Condulis

analyst
#79

I appreciate you letting me jump in. I apologize for asking yet another thing about the REMS. From what it sounds like, the request from the FDA arrived somewhat after the mid-cycle review took place. Am I understanding that correctly? I'm just curious whether you're able to share any details regarding that mid-cycle review — specifically about conversations concerning whether a REMS was needed or not — and I'd simply like to know if there's anything more you can offer. Thank you.

Robert Blum

executive
#80

Sure. My sense is that we've already shared whatever details we're able to share. As you're aware, following the mid-cycle review meeting, we filed an 8K. We made clear that a REMS had been submitted by us, and once it was received, the response we got was that it qualifies as a major amendment. My thinking is that this is everything we're in a position to say right now. I'm hoping that suffices. It feels like we might be focusing a bit too much on this topic at this point. I genuinely believe we will aim to keep using the same phrasing regarding these disclosures that we've now established.

Jim Condulis

analyst
#81

All makes sense. Thank you.

Robert Blum

executive
#82

Thank you.

Jason Zemansky

analyst
#83

Hello there, and nice work on the quarter — thanks for fitting us in, and my apologies. I'd like to go back to the REMS topic. Considering all that's taken place, I realize you'd rather not get into what the FDA has communicated, but let's zoom in on the Cytokinetics angle: since the REMS became such a central issue and played a major role in mavacamten's review, why not simply build the REMS in from the start and then design around it? Looking back, with hindsight at 2020, it appears this was a gamble that was essentially sitting there the whole time.

Robert Blum

executive
#84

You're right that this was a gamble sitting there. It was deliberate and calculated. We reached a conclusion after several meetings with FDA. Keep in mind that not only do we possess considerable know-how inside Cytokinetics when it comes to these issues, but we also brought in advisors, among them former FDA officials, to weigh in. Together, all of us arrived at the view that submitting without a REMS was a sensible approach. We took into account the feedback we got regarding labeling and risk mitigation in the absence of a REMS in that submission. The NDA was accepted for filing without a REMS. As we understood could happen while FDA reviewed it, the agency did return and request a REMS. At the time, we felt we were making the correct choice by allowing AFI Campus to be differentiated and distinct in how it's positioned, while handling safety and risk mitigation through labeling. FDA has now come back and is requesting a REMS; that's fair. Having completed its review, FDA has concluded that a REMS makes sense given the mechanism. We think FDA has likewise conveyed that a REMS specific to the intrinsic pharmaceutics and inherent characteristics of AFI Campus makes sense. We have filed such a REMS. I'm not sure there's anything further we can add. I hope that addresses your question.

Jason Zemansky

analyst
#85

It does. I appreciate the color.

Robert Blum

executive
#86

Thank you.

Leland Gershell

analyst
#87

Many thanks. I'm actually going to ask something not related to REMS. Robert, I just wanted to inquire about any real-world studies you might conduct following a presumed approval of aficamten based on the 24-week SEQUOIA-HCM data — would you plan to gather real-world data that could further flesh out or clarify the benefit regarding septal reduction surgery for treated patients? Thank you.

Robert Blum

executive
#88

Yes. Enrollment in the FOREST study is still ongoing. That study's conduct keeps supporting what we consider a distinct profile for aficamten. More of those data will be seen this year. Though that wasn't a specific question from you, I do think these data support how we envision aficamten potentially enabling us to keep maintaining a distinct profile. Perhaps I'll hand it to Fady. I believe you had a specific question regarding septal reduction.

Leland Gershell

analyst
#89

Correct.

Robert Blum

executive
#90

Right. In SEQUOIA, as everyone is aware, an analysis was carried out on individuals who met the criteria for septal reduction therapy, and it demonstrated that aficamten essentially lowers that requirement by 90%, meaning 90% of those people no longer met the criteria. That same pattern has shown up once more as those individuals move into FOREST — comparable kinds of dynamics. Now that we're examining a far longer-term set of experience in FOREST, including people who didn't meet the criteria at the outset, what we expect is to gain an understanding of the natural history involved. It stands to reason that a portion of those people would eventually have started to meet the criteria. Their conditions would have deteriorated. We're able to start comparing the FOREST findings against real-world registries; we'll obtain the progression of event rates in FOREST against the progression of event rates, possibly, in other settings. My expectation is that we'll observe aficamten perhaps decelerating those rates over the long term. That will strengthen the belief that aficamten functions as a cardiac myosin inhibitor, a mechanism that modifies disease.

Stuart Kupfer

executive
#91

Great. Thank you very much.

Robert Blum

executive
#92

Thanks.

Jason Butler

analyst
#93

Hi, and thanks for fitting in my question. At the end here, I'd like to shift direction and ask about CK-586 in the Amber-HFpEF study. I suppose there are two parts to this. First, could you provide some detail on your approach for releasing data from the initial two cohorts? And I think more significantly, how ought we view those first two doses — are they effective doses, or when might we anticipate seeing something from the study that is optimally effective?

Robert Blum

executive
#94

Thanks, Jason. Fady, and Stuart as well — please go ahead and answer that.

Fady Malik

executive
#95

Right. I believe I'll mostly leave this one to Stuart. Just keep in mind that this is a phase II study. What it's really aiming to do is establish the dose and start getting some idea of efficacy. Stuart, perhaps you could pick it up from here.

Stuart Kupfer

executive
#96

Thanks, Jason. I appreciate those questions. To begin with, it shouldn't come as a surprise that we wouldn't reveal what happened in the initial two cohorts on their own, separate from the final study's findings. Our plan is to review the complete picture across all the data, and only after that will we make the results public. On your second point, as Fady mentioned, this trial involves finding the right dose along with a strategy of titrating that dose. The population we're dealing with has many comorbidities and is older than the non-obstructive HCM patients being examined in ACACIA. Our method is extremely cautious and methodical, which is typical for dose finding work — we begin at lower doses and increase them step by step, guided by what we see regarding the pharmacodynamic effect, impacts on ejection fraction, safety, and how well it's tolerated. Through this kind of methodical, safe strategy, we'll ultimately determine the proper dose to advance, judged by its benefit-risk profile.

Analyst

analyst
#97

Hello, John here, calling in on behalf of Serge. I appreciate you fielding my question. I simply want to emphasize what's now anticipated for both the U.S. and the E.U. given the ACACIA amendment. When it comes to what counts as approvable — depending on which endpoints, or possibly both, the trial must meet — are the regulators in agreement? Regarding whether KCCQ or pVO2 get viewed differently by the two agencies, is there any divergence? Thank you.

Robert Blum

executive
#98

Yes. My understanding is that the feedback we got from the regulatory agencies has been harmonized, and Fady can go into more detail, but I'll turn it over to him for his thoughts.

Fady Malik

executive
#99

Right. So again, I believe when there isn't a firm endpoint such as death or being admitted to hospital, agencies on both sides of the Atlantic want to see consistency between how someone functions and how they feel. There's no point in boosting a person's exercise capacity and pVO2 when they don't notice anything, when they get no perceived gain from it. And on the flip side, if patients do report feeling better, you'd want to know that this stems from a direct drug effect rather than from some other factor that could be off-target or something along those lines. Those endpoints have to line up. I think both sides of the Atlantic share that view. How we handled it is, honestly, we're going to hand that information over to both groups of regulators. My sense is that each has its own idea of how to get there — by naming specific endpoints, by enlarging the trial, and by aligning the primary endpoints so that both components are included. We managed to keep everyone satisfied. In the end, I think their readings of the data will wind up being quite similar.

Analyst

analyst
#100

Thank you very much.

Yasmeen Rahimi

analyst
#101

Good afternoon, everybody. I appreciate the updates. What I think we're all trying to understand, given the various kinds of questions regarding the REMS, is whether this was simply a procedural slip-up — meaning they ought to have instructed you to file it, but didn't, and you didn't file it either, since your intention was to comply with their guidance. Or does this warrant deeper interpretation? That's really the crux of it. Was it merely a procedural misstep that's now resolved, and everything is fine? Or is there something more to be inferred from them returning and making this request? Honestly, I can't quite work out that piece. The chain of things taking place makes sense to me. I found all of your notes extremely useful, truly. Perhaps you could help us pin down which one it is, since the way the stock is moving suggests this isn't merely procedural. Something bigger is going on. It would be great if you could say whatever you're able to.

Robert Blum

executive
#102

I can tell this is frustrating for you, and I'll do my best to respond in a helpful manner. Let me be clear — nothing went wrong. I've seen what's stirring up worry among some investors. To be clear, we see no indication whatsoever of anything improper here; this falls under a standard procedure where a sponsor corresponds with the FDA. Feedback comes back to you. You respond to that feedback by taking some action. It's entirely reasonable for the FDA to come back with a particular additional ask. From our perspective, nothing about this points to any fresh concern regarding risk and safety. Rather than handling it via the label, it's now being handled through a more formal REMS. The differentiation and the distinction—everything we thought going into the submission, at the point the submission was accepted for filing, and even at this stage during the review—all of that points to the same aficamten profile that has been coming into focus through its clinical study. Nothing the FDA has told us suggests anything different. We do think the REMS program represents a risk-management approach that is now more structured, but at its core it remains what we have been describing. I hope that goes some way toward addressing the questions and concerns. You used the word mishap. I would not say at all that this is what happened here.

Yasmeen Rahimi

analyst
#103

Okay. Thank you, Robert. Very helpful.

Robert Blum

executive
#104

Thank you.

Analyst

analyst
#105

Natalie here, filling in for Ash. Thanks, everyone, for the time and for the updates. I'd like to shift topics somewhat. My question concerns Edgewise. Specifically, we're hoping to hear your perspective on the clinical data they recently released. To be even more precise, the figures are what we're focused on. We were curious whether, if the ejection fraction measurements had been taken at peak—the way you do in your program—rather than at trough, how big a difference would that have made in their measurements, in your view? Are there any other general thoughts you'd offer regarding the data they released? Thanks.

Robert Blum

executive
#106

Yes; we did take note of what Edgewise presented; making comparative statements about AFI Campus versus an investigational drug sitting in its early phase II isn't something for us to do. To be specific, you asked about how effect on EF is measured. As you note, in our studies we've been measuring EF changes at points when we think the drug is at its more maximal effect and at Cmax exposures. I'll have Fady speak to what a delta between peak and trough might be. I trust you realize that each individual drug determines that.

Fady Malik

executive
#107

Yeah, I mean, in the case of Aficamten, the average shift in ejection fraction comes to just roughly 4%. Whatever happens from peak to trough is perhaps 1 or 2 percentage points. Speculating is tough. No measurements were taken by us at those time points. Ejection fraction is influenced by numerous factors — time of day, diurnal variation, hydration, and so on; pinning down the exact magnitude is very difficult, except to say it would have been smaller. In the same way, my expectation would be that if a drug's effect were measured at peak — any drug, whether Edgewise's drug or another — and a relationship exists, you'd observe somewhat more of an effect. That holds true for other efficacy measurements too. I think that's really the extent of what I can say. Comparisons aren't something I can truly draw there.

Analyst

analyst
#108

Great. Thank you.

Robert Blum

executive
#109

I'd like to express my appreciation to everyone for joining us on this call. My hope is that the questions you had on your mind before dialing in have now been clarified. Clearly, we covered quite a few subjects, and that includes a discussion regarding REMS. It's my hope that you can take comfort in knowing we did the right things, as circumstances keep changing. That is both fair and sensible; we were ready because we had a contingency plan that we put into action. Having said that, our confidence remains strong when it comes to the possible approval of aficamten, and if it is approved, with a label and a REMS program that would give aficamten a distinct positioning and could allow us to carry out the commercial readiness program, though possibly with a delay of three months, but it's one we have been working toward for a long time. We feel optimistic about how that will land; the response we're seeing from applicants for our open commercial roles encourages us. At the same time, we'd direct your attention to forthcoming data from MAPLE. We're also enthusiastic about ACACIA, Omecamtiv Mecarbil, and CK-586. A great many positive developments are taking place at and around Cytokinetics. We anticipate bringing you additional updates at the right time. We appreciate your interest in this call. Operator, with that, we are ready to wrap up.

Operator

operator
#110

Thanks. That brings us to the end of today's call. We appreciate everyone joining in. You're free to hang up now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.